Can-Fite BioPharma Ltd. (CANF)

2.14
0.14 6.10
AMEX : Health Technology
Prev Close 2.28
Open 2.27
Day Low/High 2.11 / 2.37
52 Wk Low/High 0.38 / 25.95
Volume 27.22K
Avg Volume 226.60K
Exchange AMEX
Shares Outstanding 3.32M
Market Cap 7.57M
EPS -5.00
P/E Ratio 1.04
Div & Yield N.A. (N.A)

Latest News

Can-Fite Completes Patient Enrollment In Phase II NASH Study Of Namodenoson™

Can-Fite Completes Patient Enrollment In Phase II NASH Study Of Namodenoson™

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today it has completed patient enrollment in its Phase II...

Can Fite Announces Publication Of Namodenoson™ NASH Mechanism Of Action In International Journal Of Molecular Medicine

Can Fite Announces Publication Of Namodenoson™ NASH Mechanism Of Action In International Journal Of Molecular Medicine

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that the International Journal of Molecular Medicine...

 Can-Fite Presents New Data On The Treatment Of Advanced Liver Cancer With Namodenoson At The ILCA Conference

 Can-Fite Presents New Data On The Treatment Of Advanced Liver Cancer With Namodenoson At The ILCA Conference

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that the Company's Medical Director, Dr.

Can-Fite Shares Surge on Univo Accord to Develop Cannabis-Based Therapeutics

Can-Fite Shares Surge on Univo Accord to Develop Cannabis-Based Therapeutics

Two Israeli companies join forces to develop drugs to fight cancer and inflammatory, autoimmune and metabolic diseases.

Can-Fite Enters Into Strategic Agreement With Univo Pharmaceuticals To Develop Cannabinoid-Based Pharmaceuticals And Assays

Can-Fite Enters Into Strategic Agreement With Univo Pharmaceuticals To Develop Cannabinoid-Based Pharmaceuticals And Assays

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR), addressing cancer, liver, and inflammatory diseases,...

Can-Fite Reports Second Quarter 2019 Financial Results & Provides Clinical Update

Can-Fite Reports Second Quarter 2019 Financial Results & Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced financial results for the six months ended...

Can-Fite To Treat Advanced Liver Cancer Patients With Namodenoson Under Compassionate Use Setting In Israel

Can-Fite To Treat Advanced Liver Cancer Patients With Namodenoson Under Compassionate Use Setting In Israel

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that a supply of Namodenoson has been manufactured...

Can-Fite Signs Agreement With Kyongbo Pharm For The Distribution In South Korea Of Piclidenoson In The Treatment Of Psoriasis

Can-Fite Signs Agreement With Kyongbo Pharm For The Distribution In South Korea Of Piclidenoson In The Treatment Of Psoriasis

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has signed a distribution agreement with...

Can-Fite Participating In One-on-One Partnering Meetings At The BIO International Convention On June 3-6, 2019

Can-Fite Participating In One-on-One Partnering Meetings At The BIO International Convention On June 3-6, 2019

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that the Company's VP of Business Development,...

Figure 2 (Photo: Business Wire)

Figure 2 (Photo: Business Wire)

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that data from its recently completed Phase II trial in...

Can-Fite Reports First Quarter 2019 Financial Results & Provides Clinical Update

Can-Fite Reports First Quarter 2019 Financial Results & Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced financial results for the three months ended...

The Anti-NASH Effect Of Namodenoson Will Be Presented At The International Conference On Fatty Liver In Berlin

The Anti-NASH Effect Of Namodenoson Will Be Presented At The International Conference On Fatty Liver In Berlin

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that it has been selected for a podium...

Can-Fite's Phase II Liver Cancer Data Selected For Presentation At A Leading Liver Cancer Scientific Forum (ILCA)

Can-Fite's Phase II Liver Cancer Data Selected For Presentation At A Leading Liver Cancer Scientific Forum (ILCA)

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that the International Liver Cancer Association...

Can-Fite Announces Preparation For End-of-Phase II Meeting With FDA To Initiate The Phase III Liver Cancer Study For Namodenoson

Can-Fite Announces Preparation For End-of-Phase II Meeting With FDA To Initiate The Phase III Liver Cancer Study For Namodenoson

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today it is conducting preparatory work for a planned...

Can-Fite Announces ADS Ratio Change

Can-Fite Announces ADS Ratio Change

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that the Company will change the ratio of its...

Can-Fite Receives $1,000,000 Payment From CKD For Distribution Of Namodenoson In South Korea

Can-Fite Receives $1,000,000 Payment From CKD For Distribution Of Namodenoson In South Korea

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today it has received a $1,000,000 payment from Chong Kun...

Can-Fite Announces Late-Breaking Abstract Presentation On Namodenoson™ Phase II Results At The American Association Of Clinical Oncology (ASCO) Annual Meeting

Can-Fite Announces Late-Breaking Abstract Presentation On Namodenoson™ Phase II Results At The American Association Of Clinical Oncology (ASCO) Annual Meeting

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that a late-breaking abstract detailing results from...

Can-Fite BioPharma Announces $3.2 Million Registered Direct Offering

Can-Fite BioPharma Announces $3.2 Million Registered Direct Offering

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI) , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has entered into a definitive...

Can-Fite Files Annual Report For The Year Ended December 31, 2018

Can-Fite Files Annual Report For The Year Ended December 31, 2018

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that it has filed its annual report on Form...

Can-Fite Reports 2018 Financial Results & Provides Clinical Update

Can-Fite Reports 2018 Financial Results & Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced financial results for the year ended December...

Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results For Its Orphan/Fast Track Drug Namodenoson

Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results For Its Orphan/Fast Track Drug Namodenoson

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that the Phase II advanced liver cancer study did not...

Can-Fite To Participate In Bio Asia International Conference On March 5-6, 2019 In Tokyo

Can-Fite To Participate In Bio Asia International Conference On March 5-6, 2019 In Tokyo

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the Company's VP of Business...

Can-Fite Expands Its Namodenoson Distribution Deal With CKD In South Korea With NASH Indication

Can-Fite Expands Its Namodenoson Distribution Deal With CKD In South Korea With NASH Indication

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the expansion of its distribution agreement...

Can-Fite Receives Notice Of Allowance From U.S. Patent And Trademark Office For Osteoarthritis Drug

Can-Fite Receives Notice Of Allowance From U.S. Patent And Trademark Office For Osteoarthritis Drug

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has received a Notice of Allowance...

Can-Fite's Drugs' Potential Ability To Treat Cytokine Release Syndrome In Cancer Immunotherapy Published In Scientific Journal

Can-Fite's Drugs' Potential Ability To Treat Cytokine Release Syndrome In Cancer Immunotherapy Published In Scientific Journal

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that Drug Design, Development and Therapy has...

Can-Fite BioPharma CEO Letter To Shareholders

Can-Fite BioPharma CEO Letter To Shareholders

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that Pnina Fishman, Chief Executive Officer...

Can-Fite BioPharma Announces Registered Direct Offering

Can-Fite BioPharma Announces Registered Direct Offering

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI) , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has entered into a definitive...

Can-Fite: Pre-Clinical Data Positions Namodenoson As An Anti-Obesity Agent

Can-Fite: Pre-Clinical Data Positions Namodenoson As An Anti-Obesity Agent

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced new pre-clinical findings demonstrating that...

TheStreet Quant Rating: E+ (Sell)